Tarsus Pharmaceuticals, Inc. (TARS)

Envestnet Asset Management Inc. increased its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) by 15.9% during the undefined quarter, according to the company in its most recent filin...

Tarsus Pharmaceuticals, Inc. is upgraded to Strong Buy with a 12-month price target of $100/share, driven by Xdemvy's rapid commercialization. Xdemvy remains the only approved treatment for Demodex bl...

Campbell and CO Investment Adviser LLC acquired a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) in the undefined quarter, according to the company in its most recent disclosure with the ...

Tarsus Pharmaceuticals, Inc. ( TARS ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants David Nakasone - Head of Investor Relations Bobak Azamian - Co-Founder, President, CEO & C...

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.61 per share a year ago....

Delivered quarterly  XDEMVY ® net sales of approximately $119 million, up approximately 147% year-over-year...

IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 4, 2...

Tarsus Pharmaceuticals (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further streng...

TARS has passed the milestone of $100M in sales per quarter with Xdemvy. TARS guides for softer Q3'25 growth due to seasonality, but expects direct-to-consumer campaigns and reimbursement to drive str...